Home › Funds › Boston Trust Walden Corp › HALO
Boston Trust Walden Corp position in HALO
HALOZYME THERAPEUTICS INC · Health Care
Boston Trust Walden Corp reported holding 1,035,813 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$114.4M, representing 0.92% of its reported portfolio and ranking #17 among its reported holdings. Boston Trust Walden Corp has disclosed HALO holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Boston Trust Walden Corp's HALO position evolved
Boston Trust Walden Corp first disclosed a stake in HALO in Q2 2024 at 443,295 shares (US$23.2M). The position peaked in Q3 2026 at 1,035,813 shares, worth US$114.4M. Across 10 filings, Boston Trust Walden Corp increased the stake 3 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,035,813 shares valued at US$114.4M — a reduction of -47,249 shares quarter over quarter.. Notable position changes include a 54% increase in Q3 2024 (shares fell 16% over the following quarter), a 28% increase in Q4 2024 (shares rose 33% over the following quarter), a 59% increase in Q2 2026 (shares rose 41% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 443.30K | $23.21M | New |
| Q3 2024 | 682.62K | $39.07M | Add |
| Q4 2024 | 874.08K | $41.79M | Add |
| Q1 2025 | 866.87K | $55.32M | Reduce |
| Q2 2025 | 845.25K | $43.97M | Reduce |
| Q3 2025 | 833.89K | $61.16M | Reduce |
| Q4 2025 | 781.84K | $52.62M | Reduce |
| Q1 2026 | 679.56K | $43.92M | Reduce |
| Q2 2026 | 1.08M | $84.77M | Add |
| Q3 2026 | 1.04M | $114.35M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About HALO and 13F data
HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$178.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding HALO
- CONGRESS ASSET MANAGEMENT CO 2.28M sh · $251.89M · Q3 2026
- SNYDER CAPITAL MANAGEMENT L P 2.40M sh · $187.54M · Q2 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.62M sh · $178.46M · Q3 2026
- LOS ANGELES CAPITAL MANAGEMENT LLC 1.58M sh · $174.27M · Q3 2026
- Stephens Investment Management Group LLC 1.41M sh · $156.00M · Q3 2026
- GW&K Investment Management, LLC 1.14M sh · $125.86M · Q3 2026
- WASATCH ADVISORS LP 1.05M sh · $115.88M · Q3 2026
- LMR Partners LLP 45.00M sh · $65.81M · Q2 2026
More on Boston Trust Walden Corp
FAQ
How long has Boston Trust Walden Corp held HALO?
Boston Trust Walden Corp has disclosed HALO holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is Boston Trust Walden Corp's current position in HALO?
As of Q3 2026, Boston Trust Walden Corp holds 1.04M shares of HALO (HALOZYME THERAPEUTICS INC), valued at $114.35M, representing 0.92% of its reported portfolio and ranking #17.
Has Boston Trust Walden Corp been buying or selling HALO?
In the latest 13F filing (Q3 2026), Boston Trust Walden Corp reduced its position in HALO. The position peaked in Q3 2026 at 1.04M shares.
Which other funds hold HALO?
Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, SNYDER CAPITAL MANAGEMENT L P, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.